评论性文章：慢性乙型肝炎病毒感染的干扰素和核苷（酸）

StephenW

Aliment Pharmacol Ther. 2016 Aug 16. doi: 10.1111/apt.13751. [Epub ahead of print]
Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection.
Viganò M1, Invernizzi F2, Grossi G2, Lampertico P2.
Author information

    1Hepatology Division, Ospedale San Giuseppe, Università degli Studi di Milano, Milan, Italy.
    2Division of Gastroenterology and Hepatology, "A.M. e A. Migliavacca" Center for the Study of Liver Disease, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.

Abstract
BACKGROUND:

A short-term course of pegylated-interferon (Peg-IFN), or a long-term treatment with a third generation nucleot(s)ide analogue (NUC), of chronic hepatitis B (CHB) infection achieves viral suppression and may prevent disease progression. Owing to different mechanisms of action of the two regimens, a Peg-IFN and NUC combination treatment may be an attractive approach to enhance the off-treatment rates of virological and serological response.
AIM:

To review the literature on combinations of Peg-IFN plus NUC, including the simultaneous initiation of Peg-IFN and NUC in naïve patients; an 'add-on' combination, where Peg-IFN is started at variable times after the beginning of NUC; or a 'switch-to' strategy usually from NUC to Peg-IFN.
METHODS:

We performed a PubMed literature search using the following terms individually or in combination: NUC, hepatitis B virus, chronic hepatitis, interferon, pegylated-interferon, nucleos(t)ide analogues, entecavir, tenofovir. English-language articles published up to December 2015, as well as conference proceedings from international meetings were reviewed. References from selected papers were reviewed and used if relevant.
RESULTS:

While combination and NUC pre-treatment failed to increase HBsAg clearance rates, more promising results were achieved in patients under long-term effective NUC therapy.
CONCLUSION:

While Peg-IFN and nucleos(t)ide analogue combination therapy should not be recommended currently, the addition of or the switch to Peg-IFN in nucleos(t)ide analogue-treated patients with chronic hepatitis B infection may be useful option.

© 2016 John Wiley & Sons Ltd.

PMID:
    27528410
DOI:
    10.1111/apt.13751

StephenW

滋养品药理疗法。 2016年16月DOI：10.1111 / apt.13751。 [打印EPUB提前]
评论性文章：慢性乙型肝炎病毒感染的干扰素和核苷（酸）类似物IDE联合治疗的潜力。
维加诺M1，Invernizzi F2，格罗西G2，Lampertico P2。
作者信息

    1Hepatology司，Ospedale圣朱塞佩，UNIVERSITA阿布鲁Studi住宅米兰，米兰，意大利。
    胃肠病学和肝病的2区，“上午êA. Migliavacca”中心肝病基金会IRCCS钙格兰达Ospedale马焦雷位于Policlinico，UNIVERSITA阿布鲁Studi住宅米兰，意大利米兰的研究。

抽象
背景：

聚乙二醇化干扰素的短期课程（PEG-IFN），或与第三代nuc​​leot（S）IDE类似物（NUC），慢性乙肝长期治疗（CHB）感染达到抑制病毒，并可预防疾病进展。由于两种方案的不同作用机制，一个聚乙二醇干扰素和NUC联合治疗可以是一种有吸引力的方法，以提高病毒学和血清学应答的关断处理率。
目标：

要查看关于聚乙二醇干扰素加NUC，包括聚乙二醇干扰素和NUC的初治患者同时启动的组合文学;一个“附加”的组合，其中PEG-IFN在NUC开始后可变次启动;或“切换到”策略通常NUC对PEG-IFN。
方法：

NUC，乙型肝炎病毒，慢性肝炎，干扰素，聚乙二醇化干扰素，核苷（酸）类似物，恩替卡韦，替诺福韦：我们使用下列术语单独或组合进行搜索PubMed文献检索。公布截至2015年12月的英语文章，以及来自国际会议会议记录进行了审查。从入选论文参考文献进行了审查，如果相关使用。
结果：

虽然组合和NUC预处理未能提高HBsAg清除率，更有希望的结果是患者在长期有效的治疗NUC实现。
结论：

虽然聚乙二醇干扰素和核苷（酸）类似物IDE联合治疗不应目前推荐，加入或核苷改用聚乙二醇干扰素（T）IDE类似物治疗的慢性乙肝感染可能是有用的选项。

©2016年约翰·威利父子有限公司

结论：
    27528410
DOI：
    10.1111 / apt.13751